| Stelljes, Matthias |
| Recruiting | 3 | 210 | Europe | MC0518, BAT | medac GmbH | Steroid-refractory Acute Graft-versus-host Disease | 08/27 | 08/30 | | |
GRAPPA, NCT05153226: GvHD Prophylaxis in Unrelated Donor HCT: Randomized Trial Comparing PTCY Versus ATG |
|
|
| Active, not recruiting | 3 | 640 | Europe | Cyclophosphamide, all brands, ATG, ATG Grafalon | DKMS gemeinnützige GmbH | Graft Vs Host Disease, Peripheral Blood Stem Cell Transplantation, AML, MDS, MDS/MPN, CMML | 06/25 | 12/26 | | |
AlloRelapseMM, NCT05675319: Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy |
|
|
| Recruiting | 3 | 482 | Europe | Allogeneic Stem Cells, carfilzomib/lenalidomide/dexamethasone (KRD), elotuzumab/lenalidomide/dexamethasone (ERD), daratumumab/bortezomib/dexamethasone (DVD), daratumumab/lenalidomide/dexamethasone (DRD), ixazomib/lenalidomide/dexamethasone (IRD), pomalidomide/bortezomib/dexamethasone (PVD), carfilzomib/daratumumab/dexamethasone (KDD), Autologous Stem Cells, daratumumab/pomalidomide/dexamethasone (DPD), isatuximab/carfilzomib/dexamethasone (Isa-KD), selinexor/bortezomib/dexamethasone (SVD) | Universitätsklinikum Hamburg-Eppendorf, Gemeinsamer Bundesausschuss (G-BA), Staburo GmbH | Multiple Myeloma | 03/28 | 03/33 | | |
| Completed | 2/3 | 98 | Europe | Peripheral blood stem cells, PBSC | DKMS gemeinnützige GmbH | AML, ALL, MDS | 04/24 | 04/24 | | |
NCT04232241: Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia |
|
|
| Recruiting | 2 | 440 | Europe, RoW | Allogeneic Stem Cell Transplantation | Universitätsklinikum Hamburg-Eppendorf, DKMS Stiftung Leben Spenden, Clinical Trial Center North (CTC North GmbH & Co. KG) | Acute Myeloid Leukemia in Remission, Acute Lymphoblastic Leukemia in Remission, Myelodysplastic Syndromes | 11/22 | 11/24 | | |
| Active, not recruiting | 2 | 168 | Europe, RoW | MB-CART2019.1, R-GemOx or BR plus polatuzumab vedotin, Rituximab, Gemcitabine, Oxaliplatin, Polatuzumab vedotin, Bendamustine, Rituximab | Miltenyi Biomedicine GmbH, ICON plc | Diffuse Large B-cell Lymphoma | 12/24 | 07/29 | | |
| Recruiting | 2 | 65 | Europe | Inotuzumab ozogamicin | Nicola Goekbuget, Pfizer Pharma GmbH | Precursor Cell Lymphoblastic Leukemia | 06/25 | 12/25 | | |
| Recruiting | 1/2 | 48 | Europe | MB-CART19.1, CD19-targeting CAR T cells, Anti-CD19 CAR T cells | Miltenyi Biomedicine GmbH | Acute Lymphoblastic Leukemia Recurrent, B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory, Chronic Lymphocytic Leukemia Recurrent, Chronic Lymphocytic Leukemia Refractory | 12/24 | 12/24 | | |
| Recruiting | N/A | 250 | Europe, RoW | | University of Jena | Chronic Myeloid Leukemia in Myeloid Blast Crisis | 06/24 | 06/24 | | |
| Domagk, Dirk |
| Completed | N/A | 190 | Europe | Functional endoscopy | University Hospital Muenster | Reflux Disease, Reflux, Gastroesophageal, Reflux, Laryngopharyngeal | 01/24 | 01/24 | | |
| Enrolling by invitation | N/A | 1254 | Europe | | Universität Münster, University of Kiel, University of Copenhagen, Johannes Gutenberg University Mainz, University Hospital Muenster | Post-ERCP Acute Pancreatitis | 12/25 | 07/26 | | |
| Wittmann, Maria |
| Recruiting | 3 | 2470 | Europe | red blood cell transfusion trigger | Johann Wolfgang Goethe University Hospital, Wuerzburg University Hospital | Transfusion-dependent Anemia, Surgery, Anemia | 12/24 | 12/25 | | |
NCT05546359 / 2022-002947-23: Study of Intravenous Amisulpride for Prophylaxis of Post-operative Nausea and Vomiting (PONV) in Pediatric Patients |
|
|
| Recruiting | 2/3 | 410 | Europe, Canada, US | Amisulpride Injection, Barhemsys, Dexamethasone, Decadron | Acacia Pharma Ltd, Amicus CD LLC, Premier Research Group plc | Nausea and Vomiting, Postoperative | 06/25 | 12/25 | | |
MODIFYCSX, NCT06279793: Intravenous Fish Oil Based Lipid Emulsion to Enhance Recovery in High-Risk Cardiac Surgery Patients |
|
|
| Recruiting | 2 | 120 | Europe | Long-chain n-3 fatty acids, Omegaven®, Intravenous 0.9% Sodium Chloride, Saline Infusion | GCP-Service International West GmbH, University Hospital, Bonn, University Hospital Muenster, University Hospital Goettingen, University Hospital Schleswig-Holstein, Charite University, Berlin, Germany, Wuerzburg University Hospital | Cardiac Surgery, High Risk Patients, Intensive Care Unit, Cardiopulmonary Bypass, Valve Surgeries | 12/24 | 12/25 | | |
| Lenz, Georg |
TRIANGLE, NCT02858258: ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma |
|
|
| Recruiting | 3 | 870 | Europe | R-CHOP/R-DHAP, rituximab, CHOP, DHAP, Ibrutinib (Induction), Imbruvica, ASCT conditioning, THAM or BEAM, Ibrutinib (Maintenance) | Prof. Dr. M. Dreyling (co-chairman), LMU Klinikum | Mantle Cell Lymphoma | 05/21 | 05/26 | | |
|
COPA-R-CHOP, NCT04263584: Copanlisib in Combination With Rituximab and CHOP Chemotherapy in Patients With Previously Untreated DLBCL |
|
|
| Active, not recruiting | 2 | 62 | Europe | Copanlisib, R-CHOP Chemotherapy | University Hospital Muenster, Bayer | Diffuse Large B Cell Lymphoma | 04/25 | 04/25 | | |
| Bögemann, Martin |
PREPARE, NCT03013946 / 2016-000399-28: Role of PRoactivE Coaching on PAtient REported Outcome in Advanced or Metastatic RCC Treated With Sunitinib or a Combination of Pembrolizumab + Axitinib or Avelumab + Axitinib in First Line Therapy |
|
|
| Recruiting | 3 | 430 | Europe | Concomitant coaching | AIO-Studien-gGmbH, Pfizer, Crolll Gmbh | Renal Cell Carcinoma, Metastatic, Renal Cell Cancer, Recurrent | 01/24 | 07/24 | | |
ARASAFE, NCT05676203: A Trial Comparing Docetaxel 75 mg/m2 (3w) Versus Docetaxel 50 mg/m2 (2w) in Combination With Darolutamide + ADT in mHSPC Patients |
|
|
| Recruiting | 3 | 250 | Europe | Standard ADT (androgen deprivation therapy), Standard Darolutamide, Docetaxel | Jena University Hospital, Bayer | Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) | 07/25 | 01/27 | | |
CYCLONE 3, NCT05288166: A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer) |
|
|
| Active, not recruiting | 3 | 900 | Europe, Canada, Japan, US, RoW | Abemaciclib, LY2835219, Abiraterone, Prednisone or Prednisolone, Placebo for Abemaciclib | Eli Lilly and Company | Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Androgens, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Abiraterone Acetate, Steroid Synthesis Inhibitors, Cytochrome P-450, Enzyme Inhibitors, Prednisone, Prednisolone, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6 | 02/24 | 10/27 | | |
| Recruiting | 3 | 300 | Europe | Darolutamide 300 mg, Nubeqa®, Placebo, Androgen deprivation therapy, ADT | UNICANCER, Bayer | Prostate Cancer Metastatic | 03/28 | 09/37 | | |
| Active, not recruiting | 2 | 190 | Europe | Standard of care, Apalutamide 60Mg Tab | Universität Münster, Janssen Pharmaceutica N.V., Belgium | Prostatic Neoplasms | 11/28 | 11/28 | | |
